BRPI0415825A - novos derivados de tetrahidroespiro{piperidino-2,7'-pirrol[3,2b]piridina } e novos derivados de indol úteis no tratamento de distúrbios relacionados ao receptor 5-ht6 - Google Patents

novos derivados de tetrahidroespiro{piperidino-2,7'-pirrol[3,2b]piridina } e novos derivados de indol úteis no tratamento de distúrbios relacionados ao receptor 5-ht6

Info

Publication number
BRPI0415825A
BRPI0415825A BRPI0415825-3A BRPI0415825A BRPI0415825A BR PI0415825 A BRPI0415825 A BR PI0415825A BR PI0415825 A BRPI0415825 A BR PI0415825A BR PI0415825 A BRPI0415825 A BR PI0415825A
Authority
BR
Brazil
Prior art keywords
new
derivatives
related disorders
piperidino
receptor
Prior art date
Application number
BRPI0415825-3A
Other languages
English (en)
Inventor
Johansson Gary
Brandt Peter
Dykes Graeme
Nilsson Bjoern
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of BRPI0415825A publication Critical patent/BRPI0415825A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"NOVOS DERIVADOS DE TETRAHIDROESPIRO{PIPERIDINO-2,7<39>PIRROL¢3,2-b!PIRI DINA} E NOVOS DERIVADOS DE INDOL úTEIS NO TRATAMENTO DE DISTúRBIOS RELACIONADOS AO RECEPTOR 5-HT6". A presente invenção refere-se a compostos de fórmula (I): onde U, P, W~ 1~, W~ 2~, W~ 3~, V, Y, Z, R¬ m¬ e R¬ m<39>¬ são como descritos no relatório descritivo, a composições farmacêuticas compreendendo os compostos, a processos para sua preparação, bem como ao uso dos compostos para a preparação de um medicamento contra distúrbios relacionados ao receptor 5-HT~ 6~.
BRPI0415825-3A 2003-10-20 2004-10-20 novos derivados de tetrahidroespiro{piperidino-2,7'-pirrol[3,2b]piridina } e novos derivados de indol úteis no tratamento de distúrbios relacionados ao receptor 5-ht6 BRPI0415825A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0302760A SE0302760D0 (sv) 2003-10-20 2003-10-20 New compounds
US52312603P 2003-11-18 2003-11-18
PCT/SE2004/001508 WO2005037834A1 (en) 2003-10-20 2004-10-20 NOVEL TETRAYDROSPIRO{PIPERIDINE-2,7’ -PYRROLO[3,2-b]PYRIDINE DERIVATIVES AND NOVEL INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF 5-HT6 RECEPTOR -RELATED DISORDERS

Publications (1)

Publication Number Publication Date
BRPI0415825A true BRPI0415825A (pt) 2007-01-02

Family

ID=34467906

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415825-3A BRPI0415825A (pt) 2003-10-20 2004-10-20 novos derivados de tetrahidroespiro{piperidino-2,7'-pirrol[3,2b]piridina } e novos derivados de indol úteis no tratamento de distúrbios relacionados ao receptor 5-ht6

Country Status (13)

Country Link
US (1) US20060148818A1 (pt)
EP (1) EP1675856A1 (pt)
JP (1) JP2007509140A (pt)
CN (1) CN1871236A (pt)
AU (1) AU2004281252A1 (pt)
BR (1) BRPI0415825A (pt)
CA (1) CA2540861A1 (pt)
EA (1) EA200600811A1 (pt)
IL (1) IL174593A0 (pt)
MX (1) MXPA06004361A (pt)
NO (1) NO20062239L (pt)
SE (1) SE0302760D0 (pt)
WO (1) WO2005037834A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001296193B2 (en) * 2000-10-20 2006-04-27 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy
CN1826322B (zh) 2003-07-22 2012-04-18 艾尼纳制药公司 用于预防和治疗相关病症而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物
CA2655694C (en) * 2006-07-03 2014-12-16 Biovitrum Ab (Publ) 1,4-substituted indoles useful for modulation of the 5-ht6 receptor
JP2010508344A (ja) * 2006-10-30 2010-03-18 ビオヴィトルム・アクチボラゲット（プブリクト） ８−スルホニル−１，３，４，８−テトラヒドロ−２ｈ−［１，４］オキサゼピノ［６，７−ｅ］インドール誘導体、および５−ｈｔ６受容体リガンドとしてのその使用
JP2010515673A (ja) * 2007-01-08 2010-05-13 スベン ライフ サイエンシズ リミティド ４−（ヘテロシクリル）アルキル−ｎ−（アリールスルホニル）インドール化合物および５−ｈｔ６リガンドとしてのその使用
EP2120950B1 (en) * 2007-03-21 2012-07-04 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain
KR20090123977A (ko) * 2007-03-23 2009-12-02 애보트 게엠베하 운트 콤파니 카게 세로토닌 5-ｈｔ6 수용체의 조절에 반응하는 장애를 치료하는데 적합한 아제티딘 화합물
WO2009034581A1 (en) * 2007-09-11 2009-03-19 Suven Life Sciences Limited Substituted indolyl compounds and their use as 5-ht6 ligands
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
EP2638014B1 (en) 2010-11-08 2017-01-04 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ror-gamma activity and the treatment of diseases
AU2013259624B2 (en) 2012-05-08 2017-10-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
KR20150007300A (ko) 2012-05-08 2015-01-20 머크 샤프 앤드 돔 코포레이션 Ror감마 활성의 억제를 위한 테트라히드로나프티리딘 및 관련 비시클릭 화합물 및 질환의 치료
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
CN104725295B (zh) 2013-12-20 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
JP6728061B2 (ja) 2014-05-05 2020-07-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
SG11201610407QA (en) 2014-07-08 2017-01-27 Sunshine Lake Pharma Co Ltd Aromatic heterocyclic derivatives and pharmaceutical applications thereof
JP2018510135A (ja) 2015-02-11 2018-04-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害剤としての置換ピラゾール化合物及びその使用
EP3292119A4 (en) 2015-05-05 2018-10-03 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
US10611740B2 (en) 2015-06-11 2020-04-07 Lycera Corporation Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
AU2016276966A1 (en) 2015-06-12 2018-01-18 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
JP2018531958A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用
AU2016344111A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
CA3002850A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof
CN109053534A (zh) * 2018-08-01 2018-12-21 苏州盖德精细材料有限公司 一种医药中间体4-硝基吲哚的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191141B1 (en) * 1999-08-12 2001-02-20 Nps Allelix Corp. Azaindoles having serotonin receptor affinity
AU2001296193B2 (en) * 2000-10-20 2006-04-27 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy
KR100822655B1 (ko) * 2000-11-02 2008-04-17 와이어쓰 5-하이드록시트립타민-6 리간드로서의 1-아릴설포닐- 또는 1-알킬설포닐-헤테로사이클릴벤즈아졸, 이의 제조방법 및 이를 포함하는 약제학적 조성물
ES2271124T3 (es) * 2000-11-24 2007-04-16 Smithkline Beecham Plc Compuestos indolil-sulfonilicos utiles en el tratamiento de trastornos del snc.
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
JP4323810B2 (ja) * 2001-04-20 2009-09-02 ワイス ５−ヒドロキシトリプトアミン−６リガンドとしてのヘテロシクリルオキシ−、−チオキシ−および−アミノベンザゾール誘導体
HUP0303801A2 (hu) * 2001-04-20 2004-03-01 Wyeth Heterociklusos alkoxi-, alkil-tio- és alkil-amino-benzazol-származékok, mint 5-hidroxi-triptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US7144883B2 (en) * 2001-06-11 2006-12-05 Biovitrum Ab Bicyclic sulfonamide compounds
WO2002102774A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
EP1513809A1 (en) * 2002-06-05 2005-03-16 F. Hoffmann-La Roche Ag 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
EP1513828A1 (en) * 2002-06-20 2005-03-16 Biovitrum AB New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Also Published As

Publication number Publication date
IL174593A0 (en) 2006-08-20
SE0302760D0 (sv) 2003-10-20
WO2005037834A1 (en) 2005-04-28
CN1871236A (zh) 2006-11-29
EP1675856A1 (en) 2006-07-05
NO20062239L (no) 2006-06-21
MXPA06004361A (es) 2006-06-27
AU2004281252A1 (en) 2005-04-28
US20060148818A1 (en) 2006-07-06
CA2540861A1 (en) 2005-04-28
JP2007509140A (ja) 2007-04-12
EA200600811A1 (ru) 2006-10-27

Similar Documents

Publication Publication Date Title
BRPI0415825A (pt) novos derivados de tetrahidroespiro{piperidino-2,7&#39;-pirrol[3,2b]piridina } e novos derivados de indol úteis no tratamento de distúrbios relacionados ao receptor 5-ht6
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
NO20015379D0 (no) Indolinderivater som progesteronantagonister
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
BRPI0511532A (pt) composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia de distúrbios gastrointestinais funcionais e de sìndrome do intestino irritável em um animal de sangue quente, e para a preparação de um composto
NO20082445L (no) Neuropeptid-2 reseptor-agonister
WO2006086488A3 (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
RS20070076A (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
DK1778680T3 (da) Spirocykliske cyclohexaderivater
UA83862C2 (ru) Производные тиазола как модуляторы рецепторов канабиноидов
BRPI0417833A (pt) novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
WO2007054257A3 (en) Indene derivatives, their preparation and use as medicaments
SE0402762D0 (sv) Indazole sulphonamide derivatives
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
WO2007079400A8 (en) Self-adhesive protective substrate
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BRPI0517100A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para preparar um composto, composição farmacêutica, e, métodos para tratar um paciente sofrendo de distúrbios e de deficiência
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
NO20055997L (no) Diarylmetylidenpiperidinderivater og deres anvendelse som opiodreseptoragonister
BRPI0516057A (pt) derivados de indol como inibidores da ciclase de adenilato solúvel
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]